Differential Expression of miRNAs in Papillary Thyroid Carcinoma Compared to Multinodular Goiter Using Formalin Fixed Paraffin Embedded Tissues

AbstractmicroRNAs (miRNAs) are approximately 22 nt RNAs that negatively regulate target gene expression. Their dysregulation has been implicated in the pathogenesis of a number of human cancers, including papillary thyroid carcinoma (PTC). Whereas previous studies using microarray technologies have largely relied on the ability to procure fresh tissue at the time of surgery to characterize miRNA signatures in PTC, we exploited the ability to procure sufficient miRNA from formalin-fixed paraffin-embedded (FFPE) tissue to describe a series of miRNAs whose expression is dysregulated in PTC compared to benign proliferative multinodular goiter (MNG). We identified 13 miRNAs upregulated and 26 miRNAs downregulated in PTC versus MNG. These include miRNA-21, miRNA-31, miRNA-221, and miRNA-222. Their dysregulation was further validated by real time RT-PCR analysis in an independent set of FFPE tissues. Many of these have previously been described in fresh tissue studies as altered in PTC, confirming the utility of this approach. These results further highlight the applicability of miRNA expression patterns as potential markers of human cancer, and our results suggest that FFPE tissues are suitable resources for such miRNA expression analyses. The ability to utilize FFPE tissue in the molecular characterization of human malignancy will unlock a rich resource for future cancer studies.

[1]  A. Gill,et al.  Detection of the PAX8-PPARγ Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas , 2003 .

[2]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[3]  A. Pinchera,et al.  RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  Shamit Soneji,et al.  Microrna expression distinguishes between germinal center B cell‐like and activated B cell‐like subtypes of diffuse large B cell lymphoma , 2007, International journal of cancer.

[5]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[6]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[8]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[9]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[10]  H. Suárez.  Genetic alterations in human epithelial thyroid tumours , 1998, Clinical endocrinology.

[11]  T. Fahey,et al.  Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. , 2006, The Journal of molecular diagnostics : JMD.

[12]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[13]  B. Modan,et al.  Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood. , 2004, The Journal of clinical endocrinology and metabolism.

[14]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  N. Lemoine,et al.  High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. , 1989, Oncogene.

[16]  N. Berger,et al.  RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH , 2000, Cytogenetic and Genome Research.

[17]  D. Sidransky,et al.  BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment , 2004, Modern Pathology.

[18]  C. Esapa,et al.  Prevalence of Ras mutations in thyroid neoplasia , 1999, Clinical endocrinology.

[19]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[20]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[21]  C. Croce,et al.  MicroRNA deregulation in human thyroid papillary carcinomas. , 2006, Endocrine-related cancer.

[22]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[23]  V. Vasko,et al.  Specific pattern of RAS oncogene mutations in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[24]  M. Nikiforova,et al.  PAX8-PPAR&ggr; Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses , 2002, The American journal of surgical pathology.

[25]  G. Chiappetta,et al.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  T. Dwight,et al.  Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[27]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[28]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[29]  X. Agirre,et al.  Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.

[30]  Zissimos Mourelatos,et al.  Microarray-based, high-throughput gene expression profiling of microRNAs , 2004, Nature Methods.

[31]  A. Bounacer,et al.  High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation , 1997, Oncogene.

[32]  R. Plasterk,et al.  RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. , 2005, RNA.

[33]  A. Fischer,et al.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. , 2003, American journal of clinical pathology.

[34]  Shuomin Zhu,et al.  miR-21-mediated tumor growth , 2007, Oncogene.

[35]  T. Davison,et al.  MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.

[36]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[37]  Shinichi Suzuki,et al.  BRAF mutations in papillary carcinomas of the thyroid , 2003, Oncogene.

[38]  L. Sobrinho,et al.  Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas , 2002 .

[39]  C. Croce,et al.  The role of microRNA genes in papillary thyroid carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[41]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[42]  M. Tetzlaff,et al.  Assessing the Utility of a Mutational Assay for B-RAF as an Adjunct to Conventional Fine Needle Aspiration of the Thyroid Gland , 2006, Advances in anatomic pathology.

[43]  Arndt Borkhardt,et al.  High expression of precursor microRNA‐155/BIC RNA in children with Burkitt lymphoma , 2004, Genes, chromosomes & cancer.

[44]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[46]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[47]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[48]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[49]  M. Nikiforova,et al.  Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas , 2002, International journal of surgical pathology.

[50]  Stefano Volinia,et al.  MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[52]  K. Ghoshal,et al.  Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas , 2006, Journal of cellular biochemistry.

[53]  Z. Baloch,et al.  Fine-needle aspiration of thyroid nodules: past, present, and future. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[54]  M. Santoro,et al.  Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.